

WHO-PQ RECOMMENDED PATIENT INFORMATION LEAFLET

*This patient information leaflet focuses on uses of the medicine covered by WHO's Prequalification Team - Medicines. The recommendations for use are based on WHO guidelines and on information from stringent regulatory authorities (term to be revised).
The medicine may be authorised for additional or different uses by national medicines regulatory authorities.*

Information for the patient

[HA524 trade name] *
Lamivudine/Nevirapine/Zidovudine

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have questions about the medicine, ask your health care provider.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness seem to be the same as yours.
- If you get any side effects, talk to your health care provider. This includes unwanted effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What [HA524 trade name] is and what it is used for
2. What you need to know before you take [HA524 trade name]
3. How to take [HA524 trade name]
4. Possible side effects
5. How to store [HA524 trade name]
6. Contents of the pack and other information

1. What [HA524 trade name] is and what it is used for

[HA524 trade name] contains lamivudine, zidovudine and nevirapine. These medicines are antiviral medicines, also known as antiretrovirals, belonging to the following two groups: nucleoside analogues (NRTIs, lamivudine and zidovudine) and non-nucleoside reverse transcriptase inhibitors (NNRTIs, nevirapine). These are used to treat Human Immunodeficiency Virus (HIV) infection.

[HA524 trade name] is used as antiretroviral combination therapy for the treatment of HIV infection in adults and in children that weigh at least 25 kg.

The three medicines contained in [HA524 trade name] can be used separately with other medicines for combination treatment of HIV infection or can be used together. The dose of each active ingredient in [HA524 trade name] is the same as that recommended for the medicines when used separately. Treatment with [HA524 trade name] will only be instituted by your health care provider, when you have been shown to be stable on the three individual compounds. [HA524 trade name] reduces the amount of HIV in your body, and keeps it at a low level. It also increases CD4 cell counts. CD4 cells are a type of white blood cells that plays an important role in maintaining a healthy immune system to help fight infections. Response to treatment with [HA524 trade name] varies between patients. Your health care provider will be monitoring the effectiveness of your treatment.

[HA524 trade name] may improve your condition, but it is not a cure for your HIV infection. HIV infection is a disease spread by contact with blood or sexual contact with an infected individual. Treatment with [HA524 trade name] has not been shown to eliminate the risk of passing HIV infection on to others by sexual contact or by blood transfer. Therefore, you must continue to take appropriate precautions to avoid giving the virus to others.

2. What you need to know before you take [HA524 trade name]

Do not take [HA524 trade name]:

*Trade names are not prequalified by WHO. This is the national medicines regulatory agency's responsibility.

- if you are hypersensitive (allergic) to lamivudine, zidovudine, nevirapine or any of the other ingredients of [HA524 trade name] (see section 6, "What [HA524 trade name] contains"),
- if you have very low red blood cell count (severe anaemia) or very low white blood cell count (neutropenia).
- if you have permanent liver disease or marked changes in liver function,
- if you previously experienced liver inflammation, severe skin rash or liver injury while on treatment with nevirapine-containing products.
- Patients taking [HA524 trade name] must not take products containing rifampicin or St. John's wort (*Hypericum perforatum*) as this may stop [HA524 trade name] from working properly.

Warnings and precautions

Before using [HA524 trade name], you should have told your health care provider:

- if you have ever had or still have a liver disease (such as hepatitis),
- if you are suffering from or have ever suffered from kidney disease.

It is important that your health care provider knows about all your symptoms even when you think they are not related to HIV infection. Your health care provider may decide to prescribe lamivudine, zidovudine and/or nevirapine as separate medicines instead of [HA524 trade name].

Liver disease

During the first 10 to 12 weeks of treatment with [HA524 trade name] your health care provider will closely monitor you for the occurrence of severe and life-threatening skin reactions and serious hepatic injuries.

As [HA524 trade name] may cause changes in liver function, your health care provider will monitor the function of your liver by blood tests before and at regular intervals during treatment with [HA524 trade name]. Patients with chronic hepatitis B or C and treated with antiretroviral agents are at increased risk for severe and potentially fatal liver adverse events and may require additional blood tests for control of liver function.

You are at higher risk of severe and potentially fatal liver damage:

- if you already have raised liver function tests,
- if you have Hepatitis B or C co-infection,
- if you are female,
- if you are not already receiving effective treatment of HIV infection.

If any of these risk factors applies to you, your health care provider will monitor you more closely.

- if you have higher CD4 cell counts at the start of treatment with any nevirapine-containing product.

Therapy with any nevirapine-containing product should not be started in women with CD4 cell counts greater than 250 cells/mm³ or in men with CD4 cell counts greater than 400 cells/mm³, unless HIV is already well-treated by other drugs, and there is a switch to nevirapine, or if the benefit is considered to outweigh the risk.

If you develop clinical symptoms suggesting an injury of the liver, such as loss of appetite, nausea, jaundice (yellowing of the skin and eye white), dark urine, discoloured stools, pain and tenderness in the upper right abdomen, you should discontinue taking [HA524 trade name] and must contact your health care provider immediately.

If you have a chronic hepatitis B infection, you should not stop your treatment without instructions from your health care provider, as you may have a recurrence of your hepatitis. This recurrence may be more severe if you have serious liver disease.

Blood disorders

Since low red blood cell count (anaemia) as well as low white blood cell count (neutropenia/leucopenia) may occur due to treatment with [HA524 trade name], regular blood tests will be arranged to check whether there is a problem.

Skin reactions

[HA524 trade name] may cause skin reactions and allergic reactions, which in the worst case can be serious and life-threatening. Fatalities have been reported. Such reactions may appear in form of rash accompanied by other side effects such as fever, blistering, mouth sores, eye inflammation, facial swelling, general swelling, muscle or joint aches, a reduction in white blood cells (granulocytopenia), general feelings of illness or severe problems with liver or kidneys. If you experience a severe rash or any rash associated with other side effects of a hypersensitivity reaction, you should discontinue taking [HA524 trade name] right away and must contact your health care provider immediately.

If you develop severe liver, skin or allergic reactions while taking [HA524 trade name], never take [HA524 trade name] or any other nevirapine-containing product again without asking your health care provider.

Lactic acidosis

Females, particularly if very overweight, and patients with liver disease may be more at risk of getting a rare, but serious side effect called lactic acidosis, a build up of lactic acid in the body. If lactic acidosis occurs, it usually develops after a few months of treatment. Deep rapid breathing, drowsiness, and non specific symptoms such as nausea, vomiting and stomach pain, might indicate the development of this condition (see section 4, "Possible side effects"). While you are being treated with [HA524 trade name] your health care provider will monitor you for any signs that you may be developing lactic acidosis.

Immune reactivation syndrome

In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. If you notice any symptoms of infection, inform your health care provider immediately.

Bone problems

Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue). Your risk of developing this disease may be higher, e.g. when your immune system is severely compromised or when you drink alcohol regularly.

If you notice joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement, inform your health care provider.

You will need to take [HA524 trade name] every day. This medicine helps to control your condition, but it is not a cure for HIV infection. You may continue to develop other infections and other illnesses associated with HIV disease (e.g. opportunistic infections). These will require specific and sometimes preventive treatment. You should keep in regular contact with your health care provider. Do not stop taking your medicine without first talking to your health care provider.

You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your health care provider the precautions needed to avoid infecting other people.

Other medicines and [HA524 trade name]

Please tell your health care provider if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. These may affect the action of [HA524 trade name], or [HA524 trade name] may affect their action.

[HA524 trade name] must not be taken with rifampicin.

[HA524 trade name] must not be taken with herbal preparations containing St. John's Wort.

[HA524 trade name] should not be taken with the following agents:

- stavudine, emtricitabine, efavirenz, several protease inhibitors (e.g. tipranavir/rtv, atazanavir/rtv, fosamprenavir, indinavir), ribavirin (antiviral agents),
- ketoconazole, itraconazole (antifungals),
- probenecid (uric acid lowering agent).

[HA524 trade name] may also interact with the following medicines and may make any side effects worse or may impact on the other agent's efficacy:

- oral contraceptives (“the pill”). Therefore, you should employ an alternative contraceptive method such as barrier contraception (e.g. condoms), if you are taking [HA524 trade name].
- fluconazole (antifungal medicine),
- clarithromycin, rifabutin (antibiotics),
- artemisinins, amodiaquine/artesunate, quinine, lumefantrine, halofantrine, atovaquone (antimalarials),
- phenytoin, valproic acid (anticonvulsants),
- warfarin (medicine for prophylaxis of blood clots),
- doxorubicin (anti-cancer medicine).

[HA524 trade name] with food and drink

[HA524 trade name] may be taken with or without food.

Pregnancy and breast-feeding

If you become pregnant, or are planning to become pregnant, you must contact your health care provider to discuss the potential benefits and risks of your antiretroviral therapy to you and your child.

If you have taken [HA524 trade name] during your pregnancy, your health care provider may request regular visits to monitor the development of your child. Such visits may include blood tests and other diagnostic tests.

In children whose mothers took nucleoside and nucleotide analogues during pregnancy, the benefit of the reduced risk of being infected with HIV is greater than the risk of suffering from side effects.

If you are interested in breastfeeding your baby, you should discuss the risks and benefits with your healthcare provider.

Driving and using machines

[HA524 trade name] may cause side effects such as drowsiness or headache that can impair your ability to drive and to use machines.

3. How to take [HA524 trade name]

Always take this medicine exactly as your health care provider told you. Check with your health care provider if you are not sure.

The recommended dose of [HA524 trade name] in adults and children with a body weight of 25 kg or more is one tablet twice daily.

Tablets should be swallowed whole and neither be split nor crushed

Children:

[HA524 trade name] is not indicated for children weighing less than 25 kg, since appropriate dose reductions cannot be made.

Dose adjustments:

If your dose of [HA524 trade name] needs to be reduced, for example if you have kidney problems or discontinuation of therapy with one of the active substances of [HA524 trade name] is necessary, then your medicine may be changed to separate preparations of lamivudine, zidovudine and nevirapine, which are available as tablets/capsules and liquid formulations for oral use.

The tablets can be taken with or without food.

If you take more [HA524 trade name] than you should

If you have taken too many tablets or if someone accidentally swallows some, there is no immediate danger. However, you should contact your health care provider or the nearest hospital emergency department for further advice.

If you forget to take [HA524 trade name]

If you accidentally miss a dose and notice within 6 hours take the missed dose as soon as possible. Take the next regular dose as scheduled. If you notice later, then simply take your normal dose when the next one is due. Do not take a double dose to make up for forgotten individual doses.

If you stop taking [HA524 trade name]

Because your medicine controls and does not cure your condition, you will normally need to take it continuously. You should not stop treatment unless your health care provider tells you to.

If you have any further questions on the use of this product, ask your health care provider.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. When treating HIV infection, it is not always possible to differentiate between unwanted effects caused by [HA524 trade name], and those caused by any other medicines you may be taking at the same time, and by the HIV disease. For this reason, it is important that you inform your health care provider of any change in your health.

The major side effects of [HA524 trade name] are severe and life-threatening cutaneous reactions and serious hepatic injuries. These occur mainly in the first 10 to 12 weeks of treatment with [HA524 trade name]. This is therefore an important period which requires close surveillance (see section 2, “Warnings and precautions”).

The most *commonly* reported (greater than 1 in every 100 patients treated) side effects are hypersensitivity reactions (including general weakness, low blood pressure, hives and swelling of the face), fatigue, headache, nausea, vomiting, stomach pain, diarrhoea, fever, rash (red, raised or itchy), increase in certain liver enzymes muscle pain and other muscle disorders, dizziness, cough, nasal symptoms, tiredness, difficulty sleeping, hair loss, anaemia (low red blood cell count) and neutropenia (low white blood cell count). If the number of red blood cells is reduced, you may have symptoms of tiredness or breathlessness and a reduction in your white blood cell count can make you more prone to infections.

The following side effects are *uncommon* (between 1 in 1000 and 1 in 100 patients treated): flatulence, breathlessness, general aches and pains, joint pain, and decrease of platelets (blood cells important for blood clotting). If you have a low platelet count you may notice that you bruise more easily.

There are *rare* reports (between 1 in 10 000 and 1 in 1000 patients treated) of patchy colour changes inside the mouth, nail and skin colour changes, a blood disorder called pure red cell aplasia, heartburn, chest pain (possibly indicating a heart muscle disease called cardiomyopathy), breakdown of muscle tissue, liver disorders such as enlarged liver, fatty liver, inflammation of the liver (hepatitis), inflammation of the pancreas, sweating, flu-like feeling, drowsiness, passing urine more frequently, breast enlargement in male patients, chest pain, chills, loss of appetite, taste changes, tingling in the limbs, convulsions, inability to concentrate, depression and feeling anxious, a build-up of lactic acid in the body known as lactic acidosis (see section 2, “What you need to know before you take [HA524 trade name]”).

Very rarely (in less than 1 in 10 000 patients treated) a blood disorder called aplastic anaemia has been reported.

Frequency *not known*:

Combination antiretroviral therapy may also cause raised sugar in the blood, resistance to insulin and diabetes (see section 2, “What you need to know before you take [HA524 trade name]”).

Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution. These may include loss of fat from legs, arms and face, increased fat in the abdomen (belly) and around internal organs, breast enlargement and fatty lumps on the back of the neck ('buffalo hump'). The cause and long-term health effects of these conditions are not known at this time.

In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started (see section 2, "Warnings and precautions").

Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (the death of bone tissue caused by loss of blood supply to the bone). Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in moving (see section 2, "Warnings and precautions").

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your health care provider as soon as possible.

Reporting of side effects

If you get any side effects, talk to your health care provider. This includes unwanted effects not listed in this leaflet. If available, you can also report side effects directly through the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store [HA524 trade name]

Keep this medicine out of the sight and reach of children.

Do not store above 30°C.

Do not use this medicine after the expiry date stated on the label after 'EXP'. The expiry date refers to the last day of that month.

Do not throw away any medicines in wastewater or household waste. Ask your health care provider how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What [HA524 trade name] contains

The active ingredients are 150 mg lamivudine, 200 mg nevirapine and 300 mg zidovudine.

The other ingredients are:

Core tablet: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, povidone and talc.

Film coat (Opadry White, Y-1-7000): hypromellose, polyethylene glycol 400 and titanium dioxide.

What [HA524 trade name] looks like and contents of the pack

White coloured, capsule shaped, film-coated tablets engraved "ZLN" on one side and plain on the other side.

Round white opaque HDPE bottle with white opaque child resistant polypropylene cap with induction sealing liner. Pack size: 60 tablets.

Round white opaque HDPE bottle with white opaque HDPE screw closure with 7 layered induction sealing liner printed "Sealed for your protection". Pack size: 60 tablets.

Supplier

Strides Pharma Science Limited Strides House
Bilekahalli Bannerghatta Road
Bangalore – 560 076

Lamivudine/Nevirapine/Zidovudine
150mg/200mg/300mg Tablets
(Strides Pharma Science Limited), HA524

WHOPAR Part 3

November 2019

India.
Tel: +91-80-678407387290
Email: sadiq.basha@stridesshasun.com

Manufacturer

Strides Pharma Science Limited 36/7
Suragajakkanahalli Indlavadi cross
Anekal Taluk Bangalore – 562 106
India.
Tel: 91-80-67840600
Email: sadiq.basha@stridesshasun.com

Universal Corporation Limited Club Road
Past Kikuyu Post Office, Plot No.: 13777
P.O. Box: 1748-00902, Kikuyu
Kenya

For any information about this medicinal product, please contact the local representative of the supplier:

Region: East Africa

Country: Kenya
Address: M/s. Universal Corporation Ltd,
Club Road, Past Kikuyu Post Office
P.O Box 1748-00902
Kikuyu, Kenya
Contact Person: Mr. Palu Dhanani
Email: palu.dhanani@ucl.co.ke

Region: East Africa

Country: Uganda
Address: M/s. Delmaw Enterprises Limited Plot
9/5 & 6, Gathani House
Bombo Road
P.O Box No. 1574
Kampala – Uganda
Contact Person: Mr. Praveen Kumar .G
Email: delmaw1992@yahoo.co.uk

Region: East Africa

Country: Tanzania
Address: M/s. Samiro Pharmaceuticals Ltd
P.O.BOX 38062
Uhuru Street, Kariakoo, Dar-
es-Salaam, Tanzania
Contact Person: Mr. Muhammad Raza Shahid
Email: raza.samiropharma@gmail.com

Region: Central Africa

Country: DR Congo
Address: M/s. Gulf Africa investments
SARL (Division: Gulf Africa Pharma)
B.P. 14009

Lamivudine/Nevirapine/Zidovudine
150mg/200mg/300mg Tablets
(Strides Pharma Science Limited), HA524

WHOPAR Part 3

November 2019

Avenue du Marche No: PL 6356
Commune de la Gombe Kinshasa
RD- Congo
Contact Person: Mr. Dipu Janardanan Email:
dipu.janardanan@artemislife.com

Region: West Africa

Country: Nigeria
Address: M/s. Strides Lifesciences Ltd,
Chenline House
7, Obasa St. off Oba Akran Ave
Ikeja, Lagos, Nigeria
Contact Person: Mr. Smatt Aguba
Email: SP@stridesshasun.com

Region: Southern Africa

Country: Zambia
Address: M/s. Yash Pharmaceuticals Ltd Plot
27 Lilayi Road, Lusaka
P.O BOX: 34562 Zambia
Contact Person: Mr. Himanshu Patel Email:
h.patel@yashpharmaceuticals.com

This leaflet was last revised in November 2019

Detailed information on this medicine is available on the World Health Organization (WHO) web site:
<https://extranet.who.int/prequal/>.